Literature DB >> 29242964

[Bone substitute materials as local drug carriers : Current status of substitutes of various origins].

K-D Kühn1, C Berberich2, H Bösebeck2.   

Abstract

BACKGROUND: Autologous bone grafts (autografts) are used in surgery for defect filling and impaction grafting during hip socket and femur reconstruction. Because of their superior osteoinductive capacity, autografts are considered the "gold standard" for these treatments. However, because of a better cost-benefit ratio, allografts are also often used. In the case of limited donor availability for autologous or allogenic bone grafts, bone substitute materials (BSMs) are a reasonable alternative or supplement. BSM are based on or combine different substances. Growth factors of the bone morphogenetic protein family BMP are recombinant proteins that specifically induce the growth of bone and cartilage tissue. CHARACTERISTICS: One advantage of BSM is the option to combine them with several anti-infective agents. The choice of the anti-infective substance should not only be based on the antimicrobial efficacy, but should also take into account possible dose-dependent cellular and pharmacological side effects at the implantation site. Thus, microbiologists, pharmacists and surgeons should decide together which combination is the most appropriate. COMBINATION PRODUCTS: BSM with active agent additives are considered combination products that are characterized by a main effect (bone replacement function) and a secondary effect (prophylaxis of bacterial recolonization of BSM). Both functions must be thoroughly (clinically) evidenced in the course of the registration process as a class III medical device. Drug authorities evaluate the active agents, their function and corresponding indication. Currently, only a few combination products are available on the market. As a consequence of the only limited availability of such commercial combination products, surgeons in clinical practice often manually add the active agent to BSM in the theatre prior to implantation. However, such a customized addition of antibiotics places the surgeon in a situation of a manufacturer where he assumes liability for the product.

Entities:  

Keywords:  Antibiotics; Antiinfective agents; Bone Tissue; Bone morphogenetic protein; Reconstructive surgery

Mesh:

Substances:

Year:  2018        PMID: 29242964     DOI: 10.1007/s00132-017-3505-4

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  66 in total

1.  [Pyrost, a spongious, mineral bone substitute. Experimental bases and 13-year clinical experience in over 1000 cases].

Authors:  H Mittelmeier; W Mittelmeier; M Gleitz
Journal:  Orthopade       Date:  1998-02       Impact factor: 1.087

2.  Experimental implant-related osteomyelitis treated by antibiotic-calcium hydroxyapatite ceramic composites.

Authors:  F Korkusuz; A Uchida; Y Shinto; N Araki; K Inoue; K Ono
Journal:  J Bone Joint Surg Br       Date:  1993-01

3.  Biodegradable bone cements.

Authors:  L Claes; I Hoellen; A Ignatius
Journal:  Orthopade       Date:  1997-06       Impact factor: 1.087

4.  In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads.

Authors:  K Adams; L Couch; G Cierny; J Calhoun; J T Mader
Journal:  Clin Orthop Relat Res       Date:  1992-05       Impact factor: 4.176

5.  Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections.

Authors:  Michael A Rauschmann; Thomas A Wichelhaus; Volker Stirnal; Elvira Dingeldein; Ludwig Zichner; Reinhard Schnettler; Volker Alt
Journal:  Biomaterials       Date:  2005-05       Impact factor: 12.479

6.  The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets.

Authors:  Carl L Nelson; Sandra G McLaren; Robert A Skinner; Mark S Smeltzer; J Roby Thomas; Keith M Olsen
Journal:  J Orthop Res       Date:  2002-07       Impact factor: 3.494

7.  Biphasic calcium phosphate concept applied to artificial bone, implant coating and injectable bone substitute.

Authors:  G Daculsi
Journal:  Biomaterials       Date:  1998-08       Impact factor: 12.479

8.  Antimicrobial Formulations of Absorbable Bone Substitute Materials as Drug Carriers Based on Calcium Sulfate.

Authors:  D Pförringer; A Obermeier; M Kiokekli; H Büchner; S Vogt; A Stemberger; R Burgkart; M Lucke
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 9.  Ceramic Biocomposites as Biodegradable Antibiotic Carriers in the Treatment of Bone Infections.

Authors:  Jamie Ferguson; Michael Diefenbeck; Martin McNally
Journal:  J Bone Jt Infect       Date:  2017-01-01

10.  Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute: In vitro and clinical release studies.

Authors:  M Stravinskas; P Horstmann; J Ferguson; W Hettwer; M Nilsson; S Tarasevicius; M M Petersen; M A McNally; L Lidgren
Journal:  Bone Joint Res       Date:  2016-09       Impact factor: 5.853

View more
  1 in total

Review 1.  [Polymethyl methacrylate cement coating of intramedullary implants : A new technique for revision surgery with the example of a temporary knee arthrodesis. Video article].

Authors:  Markus Rupp; Nike Walter; Abdullah Ismat; Volker Alt
Journal:  Orthopade       Date:  2021-05-03       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.